After the initial clinical breakthrough with CD19-directed CAR-T cells in CLL in 2011 [5], this novel type of adoptive immune effector cellular therapy has become a topic of huge interest and fast development in hematology and oncology [4,18]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.